California
Biotech Insights
July 14, 2026
M&A, Deals, Partnerships: Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals (San Diego) for $10 Billion Vertex agreed to acquire Crinetics for $85.00/share in cash, an equity value of approximately $10.0 billion, picking up Crinetics’ approved acromegaly drug Palsonify along with its endocrine-disorder pipeline. Note: announced Monday, July 6 — one day before this week’s window but […]
July 7, 2026
Recent Funding: BridgeBio Pharma (SF) Raises $1 Billion in Preferred Equity Ahead of Three Drug Launches BridgeBio closed a $1B convertible preferred equity deal led by Sixth Street ($800M) and KKR’s HealthCare Royalty ($133.9M), carrying a 7% initial dividend and a conversion price of $137.79/share — more than 100% premium to its 30-day VWAP — […]
June 30, 2026
Recent Funding: Saturnus Bio (SF) Launches with $50 Million from Merck KGaA in Built-to-Buy Deal Versant Ventures has launched Saturnus Bio with $50 million from Merck KGaA to develop gene-targeted treatments for rare inherited heart muscle diseases — conditions that can cause heart failure and sudden death and currently have no approved therapies addressing their […]
June 23, 2026
Recent Funding: Kopra Bio (SF) raised $9.1M Seed Round to Advance Glioblastoma Virus Therapy UCSF spinout Kopra Bio raised $9.1M (co-led by Andreessen Horowitz and Boutique Venture Partners) to advance KB-516, a replicating retrovirus (RRV) that integrates into brain tumor cells and drives sustained IL-15 immune expression directly within the tumor microenvironment. The company, founded […]
June 18, 2026
June 16, 2026
Recent Funding: SonoThera (SF) Closes $125M Series B for Ultrasound-Mediated Genetic Medicines SonoThera (SSF) Closes $125M Series B for Ultrasound-Mediated Genetic Medicines • SonoThera, which uses its RIPPLE™ ultrasound delivery and PORE™ payload engineering to deliver DNA, RNA, and gene-editing payloads non-virally, closed an oversubscribed $125M Series B on June 10. The round was led […]
